Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Related Questions
How does this insider activity compare with that of peers in the diabetes/pharmaceutical sector?
Did the insiders net purchase or net sell shares, and what was the direction of the overall activity?
At what price were the insider transactions executed compared to the prevailing market price?
What total number of Novo Nordisk shares were bought or sold by board members and executives in this disclosure?
What potential impact could these insider transactions have on the stock’s volatility and upcoming trading sessions?
Might the disclosed trades trigger any regulatory scrutiny or affect the company’s compliance posture?
Are there any patterns or trends in insider trading that differ from previous disclosures for Novo Nordisk?
Do the disclosed insider transactions suggest confidence in the company's short‑term outlook or signal concerns?
How does the volume and price of these insider trades compare to recent market activity and average daily volume?
Could the insider buying or selling pressure impact the stock’s liquidity or short‑term price movement?